Coronavirus
Services
More
COVID-19 is an ongoing global pandemic with very limited treatment options. MERCK is working with Carbon Health to investigate possible treatment options.
Carbon Health is seeking participants in a clinical trial investigating an oral (taken by mouth) medication for adults who have COVID-19 and are not in the hospital.
Interested in participating? Please provide your contact information and a clinician will be in touch. Reimbursement for travel and expenses will be provided.
To take part in this trial (MK-4482-002), you must be 18 years or older and:
The study doctor or staff will discuss additional requirements with you. You do not need to have medical insurance to join the study.
This Playbook cover specific areas of COVID-19 vaccination program planning and implementation and provide key guidance documents and links to resources to assist those efforts.
Study participants will attend up to 9 visits for the first 29 days and receive a follow-up phone call 7 months later. They will also need to complete a symptom diary every day for 29 days.
To ensure participants qualify, we may do:
If they qualify and agree to take part, study participants will be put into a group by chance to get either the antiviral study drug or placebo. A placebo looks like the study drug but does not contain any active medicine.
Regardless of whether a patient receives the placebo or the antiviral study drug, a provider will monitor each patient with regular visits during their COVID-19 course at no cost to the patient.
Participants will:
During the 29 days in the study, the participant may have some of the following tests:
We'll schedule a virtual call about 6 months after the Treatment Phase to provide the study doctor or a member of the study staff with updates on how participants are feeling.
The MK-4482-002 study will test the safety and effectiveness of an investigational antiviral study drug which may reduce symptoms and recovery time for people who tested positive for COVID-19 in the last 5 days. This clinical study will help researchers learn whether the study drug:
This trial is being sponsored by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (“MERCK”). Taking part in this study is voluntary and the participant may stop at any time for any reason. In addition, there is no cost for the study drug or study-related care, tests and exams. Reimbursement for travel and expenses will be provided.
Sign up to receive the newest information about COVID-19 Vaccine
Choosing to take part in a clinical trial, also known as a research study, is a personal decision. It is important to learn all about it before you decide.
These frequently asked questions give information that may be helpful as you consider taking part in a clinical trial.
This Playbook cover specific areas of COVID-19 vaccination program planning and implementation and provide key guidance documents and links to resources to assist those efforts.
Please provide your name and contact information and a clinician will be in touch. Reimbursement for travel and expenses will be provided.
Please review the eligibility criteria and submit the requested information. A Carbon Health clinical team member will reach out to you at the phone number you provide within 1 business day.
To take part in this trial (MK-4482-002), you must be 18 years or older and:
The study doctor or staff will discuss additional requirements with you as well as the possible risks and benefits of trial participation.
